Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;10:16891. doi: 10.1038/s41598-020-70861-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Predicted high resistance level to antiretroviral drugs in pretreated patients from the Madrid Cohort of HIV-1 infected children and adolescents. Susceptibility level was estimated in the 162 pretreated patients with available pol sequence according to the Stanford HIVdb Interpretation Algorithm. Error bars indicate exact hybrid Wilson/Brown 95% CIs. Statistical differences: **p < 0.01 Chi-square test. Results were calculated in 48 PR and 44 RT sequences from non-transferred patients and in 109 PR and 102 RT sequences from transferred individuals at sampling. ABC abacavir, AZT zidovudine, d4T stavudine, ddI didanosine, FTC emtricitabine, TDF tenofovir disoproxil fumarate, 3TC lamivudine, DOR doravirine, EFV efavirenz, ETR etravirine, NVP nevirapine, RPV rilpivirine, ATV atazanavir, DRV darunavir, FPV fosamprenavir, IDV indinavir, LPV lopinavir, NFV nelfinavir, SQV saquinavir, TPV tipranavir, NRTI nucleoside reverse-transcriptase inhibitor, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor.